In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community ...
Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, discussed his perspective on the balance between clinical outcomes and cost considerations.
Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.
T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...
A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...
The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.
A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...
The VET PFAS Act could help older veterans with toxic exposure attain the medical treatment they need by expanding ...
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always ...
Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...
A panelist discusses how comprehensive care coordination between specialists, proactive adverse effect management, and innovative care models can optimize treatment outcomes for Lambert-Eaton ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback